The global ADME toxicology testing market accounted for USD 9.63 billion in 2023 and is expected to reach at USD 28.13 billion by 2034 with a CAGR of 10.23% during the forecast period 2024-2034. Increasing drug development activities, technological advancements, the rising prevalence of chronic diseases, a shift toward in silico and in vitro testing, a growing emphasis on personalized medicine, and collaborations and partnerships will all fuel market expansion.
Technological developments in analytical techniques, such as mass spectrometry, chromatography, and in vitro assays, have improved the accuracy and efficiency of ADME toxicology testing, allowing researchers to collect full data on drug metabolism and toxicity. For instance, Thermo Fisher announced in February 2023 that it will be making a sizable investment to help drug discovery workflows by increasing its early ADME/Tox solutions offering.
By technology, the cell culture segment accounted for the highest revenue-grossing segment in the global ADME toxicology testing market in 2023 owing to the increased adoption of in vitro testing methods and advancements in cell culture technologies, enabling more accurate and cost-effective evaluation of drug metabolism and toxicity profiles. For instance, in July 2023, Eurofins stated that it would increase its ADME/Tox testing capacity in the Asia Pacific region by constructing a new bioanalytical laboratory in Singapore. Additionally, the high throughput screening (HTS) segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for efficient and automated screening methods, which enable rapid evaluation of large compound libraries for drug discovery and development purposes.
By application, the systemic toxicity segment accounted for the highest revenue-grossing segment in the global ADME toxicology testing market in 2023 owing to the increasing emphasis on assessing the potential adverse effects of drugs on various organ systems, driving demand for comprehensive systemic toxicity testing methodologies. For instance, Covance and a top biotechnology business collaborated in June 2022 to offer ADME/Tox testing services for CAR-T cell treatments, a promising new frontier in cancer treatment. Additionally, the other toxicities segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness of the importance of assessing additional toxicities beyond systemic effects, such as genotoxicity and carcinogenicity, in drug safety evaluation, driving demand for comprehensive toxicology testing methodologies.
By the method, the cellular assay segment accounted for the highest revenue-grossing segment in the global ADME toxicology testing market in 2023 owing to the increasing adoption of cellular-based assays for evaluating drug metabolism, cytotoxicity, and efficacy, driven by their ability to mimic physiological conditions and provide relevant data for drug development. For instance, SGS SA announced in February 2023 that it will be entering the medical device testing business and perhaps testing for biocompatibility, which may involve the use of ADME/Tox principles. Additionally, the in-silico modeling segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing reliance on computational modeling for predictive toxicology assessments, driven by advancements in software algorithms, data analytics, and regulatory acceptance of in silico approaches.
By end-user, the contract research organizations (CROs) segment accounted for the highest revenue-grossing segment in the global ADME toxicology testing market in 2023 owing to the growing outsourcing trend among pharmaceutical companies to leverage specialized expertise and reduce costs in ADME toxicology testing, driving demand for services provided by contract research organizations (CROs). For instance, in March 2024, Evotec announced a partnership with a biotech business to develop targeted medicines, potentially involving ADME/Tox testing in the preclinical stage of development. Additionally, the pharmaceutical & biotechnology companies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing investment in drug development and safety assessment, coupled with expanding pipelines and a focus on personalized medicine, driving demand for ADME toxicology testing services among pharmaceutical and biotechnology companies.
North American region is anticipated to have the highest revenue share during the forecast period owing to the dominance of key pharmaceutical and biotechnology companies, robust research infrastructure, stringent regulatory standards, and increasing investments in drug development and safety assessment, driving the demand for ADME toxicology testing in the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding pharmaceutical and biotechnology sectors, increasing outsourcing of drug development activities, rising investments in healthcare infrastructure, and supportive government initiatives, driving the growth of ADME toxicology testing in the Asia Pacific region. For instance, Agilent Technologies announced a new agreement in March 2024 aimed at enhancing bioanalytical procedures, which may have consequences for ADME/Tox testing.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Technological developments in analytical techniques, such as mass spectrometry, chromatography, and in vitro assays, have improved the accuracy and efficiency of ADME toxicology testing, allowing researchers to collect full data on drug metabolism and toxicity. For instance, Thermo Fisher announced in February 2023 that it will be making a sizable investment to help drug discovery workflows by increasing its early ADME/Tox solutions offering.
By technology, the cell culture segment accounted for the highest revenue-grossing segment in the global ADME toxicology testing market in 2023 owing to the increased adoption of in vitro testing methods and advancements in cell culture technologies, enabling more accurate and cost-effective evaluation of drug metabolism and toxicity profiles. For instance, in July 2023, Eurofins stated that it would increase its ADME/Tox testing capacity in the Asia Pacific region by constructing a new bioanalytical laboratory in Singapore. Additionally, the high throughput screening (HTS) segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for efficient and automated screening methods, which enable rapid evaluation of large compound libraries for drug discovery and development purposes.
By application, the systemic toxicity segment accounted for the highest revenue-grossing segment in the global ADME toxicology testing market in 2023 owing to the increasing emphasis on assessing the potential adverse effects of drugs on various organ systems, driving demand for comprehensive systemic toxicity testing methodologies. For instance, Covance and a top biotechnology business collaborated in June 2022 to offer ADME/Tox testing services for CAR-T cell treatments, a promising new frontier in cancer treatment. Additionally, the other toxicities segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness of the importance of assessing additional toxicities beyond systemic effects, such as genotoxicity and carcinogenicity, in drug safety evaluation, driving demand for comprehensive toxicology testing methodologies.
By the method, the cellular assay segment accounted for the highest revenue-grossing segment in the global ADME toxicology testing market in 2023 owing to the increasing adoption of cellular-based assays for evaluating drug metabolism, cytotoxicity, and efficacy, driven by their ability to mimic physiological conditions and provide relevant data for drug development. For instance, SGS SA announced in February 2023 that it will be entering the medical device testing business and perhaps testing for biocompatibility, which may involve the use of ADME/Tox principles. Additionally, the in-silico modeling segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing reliance on computational modeling for predictive toxicology assessments, driven by advancements in software algorithms, data analytics, and regulatory acceptance of in silico approaches.
By end-user, the contract research organizations (CROs) segment accounted for the highest revenue-grossing segment in the global ADME toxicology testing market in 2023 owing to the growing outsourcing trend among pharmaceutical companies to leverage specialized expertise and reduce costs in ADME toxicology testing, driving demand for services provided by contract research organizations (CROs). For instance, in March 2024, Evotec announced a partnership with a biotech business to develop targeted medicines, potentially involving ADME/Tox testing in the preclinical stage of development. Additionally, the pharmaceutical & biotechnology companies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing investment in drug development and safety assessment, coupled with expanding pipelines and a focus on personalized medicine, driving demand for ADME toxicology testing services among pharmaceutical and biotechnology companies.
North American region is anticipated to have the highest revenue share during the forecast period owing to the dominance of key pharmaceutical and biotechnology companies, robust research infrastructure, stringent regulatory standards, and increasing investments in drug development and safety assessment, driving the demand for ADME toxicology testing in the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding pharmaceutical and biotechnology sectors, increasing outsourcing of drug development activities, rising investments in healthcare infrastructure, and supportive government initiatives, driving the growth of ADME toxicology testing in the Asia Pacific region. For instance, Agilent Technologies announced a new agreement in March 2024 aimed at enhancing bioanalytical procedures, which may have consequences for ADME/Tox testing.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Technology, Application, Method, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: ADME Toxicology Testing Market Report 2023 - 2034
ADME Toxicology Testing Market Analysis & Forecast by Technology 2023 - 2034 (Revenue USD Bn)
- Cell Culture
- High Throughput
- Molecular Imaging
- OMICS Technology
ADME Toxicology Testing Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Systemic Toxicity
- Renal Toxicity
- Hepatotoxicity
- Neurotoxicity
- Other Toxicities
ADME Toxicology Testing Market Analysis & Forecast by Method 2023 - 2034 (Revenue USD Bn)
- Cellular Assay
- Biochemical Assay
- In-Silica
- Ex-vivo
ADME Toxicology Testing Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals and Clinics
- Diagnostic Centers
- Pathological Labs
- Others
ADME Toxicology Testing Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. ADME Toxicology Testing Market: Technology Estimates & Trend Analysis
8. ADME Toxicology Testing Market: Application Estimates & Trend Analysis
9. ADME Toxicology Testing Market: Method Estimates & Trend Analysis
10. ADME Toxicology Testing Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America ADME Toxicology Testing Market
13. Europe Global ADME Toxicology Testing Market
14. Asia Pacific Global ADME Toxicology Testing Market
15. Latin America Global ADME Toxicology Testing Market
16. MEA Global ADME Toxicology Testing Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Charles River Laboratories International Inc.
- Eurofins Scientific
- Covance Inc. (a subsidiary of LabCorp)
- Merck KGaA
- SGS SA
- Cyprotex (a subsidiary of Evotec)
- BioIVT
- Promega Corporation
- WuXi AppTec
- GE Healthcare
- Bio-Rad Laboratories Inc.
- Agilent Technologies Inc. Absorption Systems
- Sekisui XenoTech.
